Claire from Portugal

Registered at the short selling broker Kriptomat, 2 minutes ago.

» Try Kriptomat you too
Don't show again

Merck & Co., Inc. (MRK) shares information

Merck & Co Inc

24h Change

-0.54 %


Live rate: Market closed

Stock data per Thursday 21 Sep, 2023

-0.58 (-0.54%)
US Market is closed

Live Stock price in graph for Merck & Co Inc (MRK)

  • Latest Volume

    3,467 (-99.92 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high

    107.88 USD

  • Today low

    106.42 USD

  • 52 week high

    118.05 USD

  • 52 week low

    83.02 USD

  • YTD Change


Quick links


Latest news about Merck & Co Inc

Below you can find the most recent news posts about Merck & Co Inc, primarily from US and UK based news sources.

Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer | MRK Stock News

Friday, 22 September 2023, 13:00:00
Merck, known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3
— Stock Titan

Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints

Friday, 22 September 2023, 12:59:35
Merck & Co Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Friday positive topline results from the Phase 3 KEYNOTE-A39 trial, which was conducted in collaboration with Seagen Inc. (SGEN) and Astellas Pharma Inc. (ALPMY.PK, ALPMY).
— RTT News

Merck succeeds in Phase 3 trial for bladder cancer therapy

Friday, 22 September 2023, 12:49:12
Merck”s Keytruda and Seagen”s Padcev met primary endpoints in a Phase 3 trial for bladder cancer, showing significant improvements over chemotherapy. Read more here.
— Seeking Alpha

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

Friday, 22 September 2023, 12:45:00
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in patients with certain types of metastatic non-small cell lung cancer. This press release features
— Wallstreet:Online

Merck: Still Fundamentally Undervalued Considering Keytruda”s Prospects

Thursday, 21 September 2023, 16:00:00
Keytruda is proving effective in treating more and more types of cancer. Read here to know how this impacts MRK stock”s revenue and profitability going forward.
— Seeking Alpha

Trading broker recommendation

We recommend that you check out as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: offer a large number of stocks for trading. Register an account today and check if they have MRK available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.